Discussing End-of-Life Care With a Patient

Article

Dr. Breitbart discusses how to have an effective end-of-life conversation with a patient.

William S. Breitbart, MD, acting chair at the department of psychiatry and behavioral sciences and chief of psychiatry service at Memorial Sloan-Kettering Cancer Center, discusses how to have an effective end-of-life conversation with a patient.

Recent Videos
4 experts in this video
4 experts in this video
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
Related Content
Univariate and multivariate analyses found that increased mortality was associated with the presence of liver metastases at baseline

Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population

Tim Cortese
August 24th 2025
Article

The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Tackling Unmet Needs in Mantle Cell Lymphoma

Tackling Unmet Needs in Mantle Cell Lymphoma

Tycel Phillips, MD
August 24th 2025
Article

Tycel Phillips, MD, highlighted the need for new therapies for patients with MCL who have relapsed on previous lines of treatment.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Another analysis excluded 7 trials that evaluated neoadjuvant radiation alone in historical cohorts and still found that pCR was not correlated with OS or DFS.

pCR Does Not Correlate With Survival in Rectal Cancer

Tim Cortese
August 23rd 2025
Article

A meta-analysis did not find any correlation between pathologic complete response and overall survival or disease-free survival in patients with rectal cancer.

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.